MEI Pharma, Inc.

Please note: The information displayed on this page might be outdated.
MEI Pharma, Inc.: Four clinical-stage oncology candidates, multiple 2021 milestones. Upcoming events include enrollment completion in the TIDAL study intended to support accelerated approval of lead candidate zandelisib (PI3K delta inhibitor) in r/r follicular lymphoma. Enrollment guided to complete in the first quarter of 2021; primary efficacy endpoint is 6 month ORR. Broadening zandelisib development activity includes addition of marginal zone lymphoma arm to TIDAL to support expansion of an accelerated approval strategy if successful, the initiation of a Phase 3 study in second line follicular and marginal zone lymphomas in mid-2021, and plans to support select investigator-initiated trials, initially in first-line DLBCL. Milestones also include Initial phase 1b data from study evaluating zandelisib with Brukinsa™ in collaboration with BeiGene. Anticipated updates in other programs include: voruciclib Initial data from the Phase 1 monotherapy and +BCL2i Phase 1b; pracinostat phase 2 MDS update from partner Helsinn; and ME-344 plan to leverage clinically demonstrated anti-tumor activity in combination with anti-VEGF.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific, USA
Clinical Stage
Phase III, Phase l or ll, Pivotal
Disease Space
DLBCL, Hematology, Marginal Zone (mzl), Oncology
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
B Cell, pi3k, Small Molecule, Targeted Therapy
Website:
Profiles:
Address:
3611 Valley Centre Drive
Suite 500
San Diego, CA 92130
United States

Company Participants at Solebury Trout Virtual Management Access Event 2021

Daniel Gold
MEI Pharma, Inc., CEO & President
Dr. Gold was appointed President, Chief Executive Officer and a director in April 2010. He joined the Company with approximately 25 years of drug discovery and development experience, most recently as President and Chief Executive Officer of Prospect Therapeutics, a mid-stage oncology company. Prior to his tenure at Prospect, Dr. Gold was founder and Chief Scientific Officer of Favrille, where he was an integral member of a team that raised more than $200 million to advance the company's lead oncology candidate through a pivotal Phase III clinical trial. He currently serves on the Board of Trustees of the Hope Funds for Cancer Research. Dr. Gold's academic qualifications include Postdoctoral Fellowships at the Dana-Farber Cancer Institute, at the Harvard School of Medicine and the Massachusetts Institute of Technology, Center for Cancer Research. He holds a Ph.D. in Pathology/Immunology from Tufts University, Boston and a bachelor's degree in Biology from the University of California Los Angeles.

Top 10 Holders of MEI Pharma, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
MPM Oncology Impact Management LP 9.56 10,137,859 35.99 13F 12/31/20
NEA Management Co. 8.05 8,533,072 30.29 13F 12/31/20
Wasatch Advisors, Inc. 5.23 5,545,767 19.69 13F 12/31/20
The Vanguard Group, Inc. 5.14 5,446,692 19.34 Funds 3/31/21
Vanguard Group, Inc. (Subfiler) 4.83 5,121,340 18.18 13F 12/31/20
BVF Partners LP 3.82 4,049,162 14.37 Stakes 12/31/20
BVF, Inc. 3.82 4,049,162 14.37 13F 12/31/20
First Light Asset Management LLC 3.58 3,793,275 13.47 13F 12/31/20
BlackRock Fund Advisors 3.45 3,658,056 12.99 13F 12/31/20
Burrage Capital Management LLC 3.02 3,205,938 11.38 13F 12/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.